The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma

BACKGROUND: Immunotherapy is revolutionising the treatment of patients diagnosed with melanoma and other cancers. The first immune checkpoint inhibitor, ipilimumab (targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)), showed a survival advantage over standard chemotherapy. Subsequently t...

Descripción completa

Detalles Bibliográficos
Autores principales: Coen, Oliver, Corrie, Pippa, Marshall, Helen, Plummer, Ruth, Ottensmeier, Christian, Hook, Jane, Bell, Sue, Sagoo, Gurdeep S., Meads, David, Bestall, Janine, Velikova, Galina, Gallagher, Ferdia A., Smith, Alexandra, Howard, Helen, Mason, Ellen, Katona, Eszter, Silva, Shobha, Collinson, Michelle, Rodwell, Simon, Danson, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246129/
https://www.ncbi.nlm.nih.gov/pubmed/34210290
http://dx.doi.org/10.1186/s12885-021-08509-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246129/
https://www.ncbi.nlm.nih.gov/pubmed/34210290
http://dx.doi.org/10.1186/s12885-021-08509-w

Ejemplares similares